drugset / Trial / NCT00592007
Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this research study is to see if adding fulvestrant (Faslodex) to erlotinib (Tarceva) is effective in patients with stage IIIb/IV Non-Small Cell Lung Cancer.
Timeline
- Start
- 2007-09
- Primary completion
- 2012-01
- Completion
- 2012-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fulvestrant | Small molecule | 250 mg | Intramuscular |
| Background | Erlotinib | Small molecule | 100 mg | Oral |
| Background | Erlotinib | Small molecule | 150 mg | Oral |